TP53 and breast carcinoma: In contrast, the ratios of individuals with TP53 pathogenic variant among patients with breast cancer aged < 31, 31–40, 41–50, and ≥ 51 years were 0–3.8%, 0–2.6%, 0–0.8%, and 0–0.2%, respectively.